XELJANZ(REGISTERED) TABLETS 5 MG SPECIAL INVESTIGATION(INVESTIGATION OF LONG-TERM USE IN PATIENTS WITH ULCERATIVE COLITIS)
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Tofacitinib (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Pfizer
- 13 Dec 2022 Status changed from active, no longer recruiting to completed.
- 15 Oct 2022 Planned End Date changed from 16 Aug 2022 to 15 Nov 2022.
- 15 Oct 2022 Planned primary completion date changed from 16 Aug 2022 to 15 Nov 2022.